References
- Tristano A. Macrophage activation syndrome: a frequent but under-diagnosed complication associated with rheumatic diseases. Med Sci Monit 2008; 14: RA27–36
- Henter JI, Horne A, Aricó M, Egeler RM, Filipovich AH, Imashuku S, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007; 48: 124–31
- Villanueva J, Lee S, Giannini EH, Graham TB, Passo MH, Filipovich A, et al. Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome. Arthritis Res Ther 2005; 7: R30–7
- Kounami S, Yoshiyama M, Nakayama K, Okuda S, Aoyagi N, Yoshikawa N. Macrophage activation syndrome in children with systemic-onset juvenile chronic arthritis. Acta Haematol 2005; 113: 124–9
- Omagari K, Ashida R, Ohi H, Minamino Y, Sasaki O, Ozono Y, et al. Successful treatment with cyclosporine in a case of hemophagocytic syndrome manifesting as severe liver dysfunction. Am J Med Sci 1997; 314: 403–7
- Dhote R, Simon J, Papo T, Detournay B, Sailler L, Andre MH, et al. Reactive hemophagocytic syndrome in adult systemic disease: report of twenty-six cases and literature review. Arthritis Rheum 2003; 49: 633–9
- Noble S, Wagstaff A. Cyclosporin: a review of its pharmacology and clinical potential in the treatment of systemic lupus erythematosus. BioDrugs 1997; 7: 483–501
- Griffiths B. The treatment of lupus with cyclosporin A. Lupus 2001; 10: 165–70
- Richaud-Patin Y, Soto-Vega E, Jakez-Ocampo J, Llorente L. P-glycoprotein in autoimmune diseases. Autoimmunity Rev 2004; 3: 188–92